We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

California Pharmas Spar Over Chinese Licensing

Law360 (March 30, 2007, 12:00 AM EDT) -- The legal wrangling between two California biopharmaceutical companies over the licensing of a cancer treatment in China has grown more intense with the filing of a counter-complaint.

Peregrine Pharmaceuticals Inc. filed suit against Cancer Therapeutics Laboratories in January in California Superior Court alleging breach of contract. The two companies entered into a joint licensing agreement in 1995 that allowed CTL to market and sell certain cancer treatments in China and Peregrine to market the same products everywhere else.

The treatment at issue is an antibody technology...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.